TY - JOUR
T1 - Comparative Effectiveness of COVID-19 Vaccines in Preventing Infections and Disease Progression from SARS-CoV-2 Omicron BA.5 and BA.2, Portugal
AU - Kislaya, Irina
AU - Casaca, Pedro
AU - Borges, Vítor
AU - Sousa, Carlos
AU - Ferreira, Bibiana I.
AU - Fonte, Ana
AU - Fernandes, Eugénia
AU - Dias, Carlos Matias
AU - Duarte, Sílvia
AU - Almeida, José Pedro
AU - Grenho, Inês
AU - Coelho, Luís
AU - Ferreira, Rita
AU - Ferreira, Patrícia Pita
AU - Borges, Cláudia Medeiros
AU - Isidro, Joana
AU - Pinto, Miguel
AU - Menezes, Luís
AU - Sobral, Daniel
AU - Nunes, Alexandra
AU - Santos, Daniela
AU - Gonçalves, António Maia
AU - Vieira, Luís
AU - Gomes, João Paulo
AU - Leite, Pedro Pinto
AU - Nunes, Baltazar
AU - Machado, Ausenda
AU - Peralta-Santos, André
N1 - Publisher Copyright:
© 2023 Centers for Disease Control and Prevention (CDC). All rights reserved.
PY - 2023/3
Y1 - 2023/3
N2 - We estimated comparative primary and booster vaccine effectiveness (VE) of SARS-CoV-2 Omicron BA.5 and BA.2 lineages against infection and disease progression. During April-June 2022, we implemented a case-case and cohort study and classified lineages using whole-genome sequencing or spike gene target failure. For the case-case study, we estimated the adjusted odds ratios (aORs) of vaccination using a logistic regression. For the cohort study, we estimated VE against disease progression using a penalized logistic regression. We observed no reduced VE for primary (aOR 1.07 [95% CI 0.93-1.23]) or booster (aOR 0.96 [95% CI 0.84-1.09]) vaccination against BA.5 infection. Among BA.5 case-patients, booster VE against progression to hospitalization was lower than that among BA.2 case-patients (VE 77% [95% CI 49%-90%] vs. VE 93% [95% CI 86%-97%]). Although booster vaccination is less effective against BA.5 than against BA.2, it offers substantial protection against progression from BA.5 infection to severe disease.
AB - We estimated comparative primary and booster vaccine effectiveness (VE) of SARS-CoV-2 Omicron BA.5 and BA.2 lineages against infection and disease progression. During April-June 2022, we implemented a case-case and cohort study and classified lineages using whole-genome sequencing or spike gene target failure. For the case-case study, we estimated the adjusted odds ratios (aORs) of vaccination using a logistic regression. For the cohort study, we estimated VE against disease progression using a penalized logistic regression. We observed no reduced VE for primary (aOR 1.07 [95% CI 0.93-1.23]) or booster (aOR 0.96 [95% CI 0.84-1.09]) vaccination against BA.5 infection. Among BA.5 case-patients, booster VE against progression to hospitalization was lower than that among BA.2 case-patients (VE 77% [95% CI 49%-90%] vs. VE 93% [95% CI 86%-97%]). Although booster vaccination is less effective against BA.5 than against BA.2, it offers substantial protection against progression from BA.5 infection to severe disease.
UR - http://www.scopus.com/inward/record.url?scp=85148678879&partnerID=8YFLogxK
U2 - 10.3201/eid2903.221367
DO - 10.3201/eid2903.221367
M3 - Article
C2 - 36737101
AN - SCOPUS:85148678879
SN - 1080-6040
VL - 29
SP - 569
EP - 575
JO - Emerging Infectious Diseases
JF - Emerging Infectious Diseases
IS - 3
ER -